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A simple analytical high-performance liquid chromatography (HPLC) method was applied for the en-
antiomeric excess determination of esomeprazole ((S)-OME), the enantiopure active ingredient con-
tained in drug products, in the presence of its potential organic impurities A-E. The enantioselective
separation was accomplished on the immobilized-type Chiralpak ID-3 chiral stationary phase (CSP)
under reversed-phase conditions. The results were evaluated and compared with those obtained by the
ofﬁcial enantioselective method of European Pharmacopoeia used as the reference for checking the
enantiomeric excess of (S)-OME. It has been established that the use of the Chiralpak ID-3 CSP allows the
determination of the enantiomeric purity of (S)-OME without any interference coming from its chiral and
achiral related substances. The analytical procedure of the drug regulatory agencies based on the AGP
CSP suffered instead from poor speciﬁcity due to overlap of the peaks pertinent to the achiral impurity A
and the chiral impurity (R)-OME (impurity F).
& 2015 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Omeprazole (OME, bis(5methoxy-2-[(4-methoxy-3,5-dimethyl-
2-pyridinyl)methyl]sulﬁnyl)-1H-benzimidazole-1yl) (Fig. 1) is a
well-known gastric proton-pump inhibitor (PPI) used in the
treatment of gastric-acid related diseases. In 2000 in Europe and
2001 in USA, AstraZeneca launched the ﬁrst enantiopure PPI, the
magnesium trihydrate salt of the (S)-enantiomer of OME, under
the Nexium brand. Compared with the corresponding racemic
drug, (S)-OME is demonstrated to have the same pharmacody-
namic properties as the corresponding racemic drug, but it has a
more favorable metabolic behavior and a more pronounced effect
on duodenal ulcers, erosive esophagitis, and gastroesophageal
reﬂux disease [1,2].
According to the monograph for esomeprazole magnesium
trihydrate active substance in European Pharmacopoeia (EP) [3],
the enantiomeric impurity of (S)-OME, namely (R)-OME, is
checked by an enantioselective HPLC method based on the use of
the AGP (100 mm  4.0 mm, 5μm) column with a mobile phase
containing a mixture of acetonitrile–pH 6 phosphate buffer (13:87,on and hosting by Elsevier B.V. Th
University.v/v). The content of (R)-OME has an acceptance criterion ﬁxed in
an upper limit of 0.6%. The monograph does not furnish any data
about the selectivity of the chiral HPLC method towards other
related substances (impurities A-E) whose structures are very si-
milar to that of the active product ingredient (API) (Fig. 1). In ad-
dition, the chiral impurity B (IMP-B) and IMP-E are reported as
racemic mixtures, even though the prochiral sulﬁde intermediate
is synthesized via an asymmetric oxidation reaction [4]. As a rule
of thumb, the chiral impurities of the (S)-OME, whatever their
origin (from synthetic or degradation steps) is, should normally
have the (S)-conﬁguration as the API does. Therefore, the ability of
the current ofﬁcial chiral method to accurately measure the en-
antiomeric excess of (S)-OME in the presence of the achiral and
the (S)-forms of chiral substance correlates, which should be a
crucial aspect of the analysis to ensure high-quality API, has yet to
be demonstrated.
Although a great number of HPLC methods have been
developed for the direct enantioseparation of OME in normal
phase, polar organic and reversed-phase conditions [5–10], the
quantitative analysis of the enantiomeric purity of (S)-OME in the
presence of its related substances is extremely challenging to achi-
eve [11].
Our group has published for the ﬁrst time the separation of (S)-
OME from its potential organic chiral and achiral impurities on theis is an open access article under the CC BY-NC-ND license
Fig. 1. Structures of (S)-OME and its potential organic impurities.
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was based on a mixture of methyl tert-butylether–ethyl acetate–
ethanol–diethylamine (60:40:5:0.1, v/v/v/v) as the mobile phase
delivered at a ﬂow rate of 1.0 mL/min. Chemo- and enantioselec-
tive HPLC separations were simultaneously achieved on an IA (250
mm  4.6 mm) column in an analysis time of about 25 min. Re-
cently, with the aim to simplify the eluent mixture and get the
analytical method more sustainable, we reported an easy way to
separate the enantiomers of OME and other three PPIs (lanso-
prazole, rabeprazole and pantoprazole) on polysaccharide-based
CSPs under water-rich conditions [13]. In particular, it was de-
monstrated that using a Chiralpak ID-3 (100 mm4.6 mm, 3 μm)
column the baseline enantioseparation of OME within 8 min could
be achieved. A volume of only 4 mL of ACN was employed for each
eluting step. The aim of this work was to compare the ability of the
two commercial available Chiralpak ID-3 and AGP CSPs to separate
the enantiomers of OME in the presence of its organic related
substances under reversed-phase conditions.2. Experimental
2.1. Chemicals and reagents
OME and the impurities shown in Fig. 1 were purchased from
the European Directorate for the Quality of Medicines and
Healthcare (EDQM) (France) and United States Pharmacopoeial
Convention, Rockville (MD). HPLC-grade solvents were used as
supplied by Aldrich (Milan, Italy). Sodium dihydrogen orthopho-
sphate and sodium phosphate dibasic salts were purchased from
Carlo Erba (Milan, Italy). HPLC enantioseparations were performed
using stainless-steel Chiralpak ID-3 (100 mm4.6 mm, 3 mm) and
Chiralpak AGP (100 mm4.0 mm, 5 mm) columns (Chiral Tech-
nologies Europe, Illkirch, France).
2.2. Instruments and chromatographic conditions
The HPLC apparatus consisted of a Dionex P580 LPG pump, an
ASI-100 T autosampler, an STH 585 column oven, a PDA-100 UV
detector or a Jasco (Jasco, Tokyo, Japan) Model CD 2095 Plus UV/CD
detector; data were acquired and processed by a Chromeleon
Datasystem (Dionex Corporation, Sunnyvale, CA). For semi-
preparative separation, a Perkin-Elmer (Norwalk, CT, USA) 200 LC
pump equipped with a Rheodyne (Cotati, CA, USA) injector, a
1000 μL sample loop, a Perkin-Elmer LC 101 oven and a Waters484 detector (Waters Corporation, Milford, MA, USA) was used.
The signal was acquired and processed by Clarity software (Da-
taApex, Prague, the Czech Republic).
Experimental conditions for semipreparative enantiosepara-
tions of OME, IMP-B and IMP-E are reported elsewhere [12].
In analytical separations, fresh standard solution of OME and
single impurities were prepared shortly before using by dissolving
1–3 mg of each analyte in the mobile phase.
2.3. Preparation of stock and standard solutions
Stock solutions of the single enantiomer of OME were prepared
by dissolving 4.97 mg in 10 mL volumetric ﬂasks with the mobile
phase and kept at 20 °C protected from light. Suitable dilutions
were carried out to obtain the ﬁnal concentrations of standard
solutions of 0.2485, 0.497, 24.85, 99.40, 248.50 and 497 μg/mL.
Standard solutions of (S)-OME were prepared and used daily for
calibration purpose from 0.1% to 200% relative to the working
concentration of 248.50 μg/mL (100%) of (S)-enantiomer of OME.
2.4. Method validation
2.4.1. HPLC operating conditions
Analytical chromatographic separations were carried out on a
Chiralpak ID-3 column (100 mm4.6 mm, 3 mm) with a mobile
phase consisting of ACN-H2O in the ratio 50:50 (v/v) at a ﬂow rate
of 1 mL/min and maintaining the column temperature at 40 °C.
The injection volume was 20 μL, sampler temperature was set at
5 °C, and the detection wavelength was set at 280 nm or 300 nm
for validation purposes.
2.4.2. Speciﬁcity
The selectivity of the analytical method was evaluated by the
analysis of a solution containing (S)-OME enantiomer and its main
related substances.
Standard solutions of (R)-OME were prepared from 0.05% to 5%
relative to the working concentration of 248.50 μg/mL (100%) of
(S)-enantiomer of OME.
2.4.3. Linearity
The linearity evaluation was performed with the standard so-
lutions of (S)-OME at the concentrations ranging from 0.2485 to
497 μg/mL with a working concentration of 248.50 μg/mL. Three
injections of each solution were made under the chromatographic
conditions described above, using an injection volume of 20 mL.
B. Gallinella et al. / Journal of Pharmaceutical Analysis 6 (2016) 132–136134The peak areas response of (S)-OME was plotted against the cor-
responding concentration and the linear regression equations
were computed.
2.4.4. Limit of determination (LOD) and limit of quantitation (LOQ)
LOD and LOQ represent the concentration of the analyte that
would yield a signal-to-noise (S/N) of 3 and 10, respectively, fol-
lowing the EP. The LOD and LOQ of (S)-OME were determined by
injecting a series of diluted solutions.
2.4.5. Precision
The precision was determined by measuring the repeatability
of retention time and peak areas on replicate injections (n¼6) of
248.50 μg/mL of (S)-OME solution. Precision was reported as
percentage of relative standard deviation (RSD%).3. Results and discussion
3.1. Analytical HPLC enantioseparation and enantiomer elution order
on the ID-3 and AGP CSPs
Because the enantiomeric elution order of the chiral IMP-B and
IMP-E of OME on the AGP CSP has not been established, we started
our research by analyzing the chiral samples in the racemic form
under the HPLC analytical method described in the EP monograph
for checking the enantiomeric purity of (S)-OME [chiral column:
AGP (100 mm4.0 mm, 5μm) column; mobile phase: acetoni-
trile–pH 6 phosphate buffer (13:87, v/v); ﬂow rate: 0.6 mL/min;
temperature: 25 °C]. The analytical results were compared with
those obtained from the enantioselective analysis of only OME on
the Chiralpak ID-3 (100 mm  4.6 mm, 3 μm) column in the
chromatographic conditions optimized in an our previous work
[column temperature: 40 °C; ﬂow rate: 1.0 mL/min; mobile phase:
acetonitrile–water (50:50, v/v)] [13].
The typical on-line CD traces and the chromatographic results
obtained using the experimental conditions described above are
shown in Fig. 2. Chromatographic results reveal that the chiral dis-
crimination ability of the ID-3 CSP was generally superior to that of
AGP CSP. The enantioselectivity factors values were high on both CSPs
just in case of OME (α¼3.11 and α¼2.97) while the resolving power
of the AGP CSP signiﬁcantly lowered for the IMP-B (α¼1.44). TheFig. 2. Typical CD traces recorded during the enantioselective HPLC of OME, IMP-B a
(100 mm4.0 mm, 5μm) (right side); detection: CD at 280 nm; ﬂow rate: 1.0 (left side)
side).enantiomers of the compound IMP-E were not separated at all on the
AGP CSP and weakly resolved on the ID-3 CSP (α¼1.10).
The enantiomer elution order of the investigated chiral com-
pounds was easily and unambiguously established by evalu-
ating the on-line CD signal monitored at 280 nm during the en-
antioselective analysis (Fig. 2). As demonstrated previously [13], at
the diagnostic wavelength of 280 nm and under reversed-phase
conditions, there is an univocal correlation between CD properties
and absolute conﬁguration of the eluting enantiomer. The ﬁrst
eluting enantiomer on the ID-3 CSP exhibited negative CD signal at
280 nm (Fig. 2). On the basis of the aforementioned strategy, its
absolute conﬁguration was determined as (S). Consequently, the
(R)-conﬁguration was assigned to the more retained enantiomer,
with positive CD signal at the same wavelength.
It is interesting to note that the (S)-enantiomer of OME was
found to be eluted later than (R)-counterpart on the AGP CSP. In
the case of the structurally related IMP-B, the enantiomer elution
order was reversed with respect to OME on the ID-3 CSP ((S)-IMP-
B was eluted later than (R)-IMP-B) whereas it was the same as that
observed on the AGP CSP. Finally, the (R)-form of IMP-E was ﬁrst
eluted on the ID-3 CSP. The availability of pure enantiomeric forms
of OME, IMP-B and IMP-E and the knowledge of their absolute
conﬁguration [11] allowed us to conﬁrm the enantiomer elution
order established by the on-line CD signal recorded at 280 nm.
3.2. Validation of the method
3.2.1. Speciﬁcity
Having established the chiral discrimination ability of ID-3 and
AGP CSPs towards the racemic samples, OME, IMP-B and IMP-E,
and identiﬁed the enantiomers of each chiral substance in the
pertinent HPLC elution proﬁle, the next step of our work was to
check the speciﬁcity of two analytical enantioselective methods
based on the ID-3 and AGP CSPs. The speciﬁcity of the analytical
methods was checked by injecting the (S)-form of OME, the en-
antiomeric impurity (R)-OME, the (S)-forms of IMP-B and IMP-E
and the achiral related substances A, C and D individually. The
obtained chromatograms are presented in Figs. 3 and 4. As can be
seen in the case of the ID-3 CSP, the retention times of the two
enantiomers of OME were clearly different from those of the re-
lated substances. Therefore, the proposed method based on the
polysaccharide-type CSP can separate the target (S)-OME from itsnd IMP-E. Columns: Chiralpak ID-3 (100 mm4.6 mm, 3μm) (left side) and AGP
and 0.6 (right side) mL/min; column temperature: 40 °C (left side) and 25 °C (right
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Fig. 3. Typical HPLC chromatograms of (S)-OME and its impurities A-F on the ID-3
CSP. Column: Chiralpak ID-3 (100 mm4.6 mm, 3μm); detection: UV at 280 nm;
ﬂow rate: 1.0 mL/min; column temperature: 40 °C.
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Fig. 4. Typical HPLC chromatograms of (S)-OME and its impurities A-F on the AGP
CSP. Column: AGP (100 mm4.0 mm, 5μm); detection: UV at 280 nm; ﬂow rate:
0.6 mL/min; column temperature: 25 °C.
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interference of the impurities A-E. Due to its speciﬁcity, it can be
applied for in-process and quality controls of the enantiomeric
purity drugs. In the case of the analytical procedure of the drug
regulatory agencies based on the AGP CSP, the peak pertinent to
the IMP-A is expected to overlap with that of (R)-OME. The peaks
interference may be sufﬁcient to corrupt the analysis of the en-
antiomeric purity of (S)-OME and to make the method non-spe-
ciﬁc. As the last remark, a very broad peak at the retention time of
about 35 min was observed for the IMP-C when eluted on the AGP
CSP.
The enantioselective HPLC system based on the immobilized
Chiralpak ID-3 CSP was partially validated and the analytical re-
sults obtained are described below.
3.2.2. Linearity
The linearity of the HPLC method was evaluated by injecting
standard concentrations of (S)- and (R)-OME samples with a
concentration ranging from 0.2485 to 497 μg/mL (0.1%–200%) and
0.12425–12.425 μg/mL (0.05%–5%), respectively. The peak area
response was plotted versus the nominal concentration of the
enantiomer. The obtained calibration curves for the (S)-OME and
(R)-OME were as follows: y¼26314xþ15171 (r2¼1.0) and
y¼26324x359.15 (r2¼1.0), where x is the concentration and y is
the peak area.3.2.3. LOD and LOQ
The LOD and LOQ were estimated to be 9.8 and 32.66 ng/mL for
(S)-OME and 33.32 and 111.06 ng/mL for (R)-OME enantiomers on
Chiralpak ID-3 CSP. In the case of the AGP CSP, the LOD and LOQ
values were 20.75 and 69.16 ng/mL for (S)-OME and 12.45 and
41.5 ng/mL for (R)-OME.
3.2.4. Precision
The precision of the HPLC method was determined by repeat-
ability for retention times, with an RSD of 0.15%, and for area, with
an RSD of 0.30%, which comply with the acceptance criteria pro-
posed (RSD not more than 2.0%).4. Conclusions
In summary, the presented work is an original extension of
previously published studies on HPLC enantioseparation of OME.
For the ﬁrst time, we have established the HPLC separation of OME
enantiomers in the presence of its potential organic impurities A-E
under reversed-phase mode. In order to achieve that, the follow-
ing objectives were necessary: (i) to separate the enantiomers of
OME and its chiral impurities on the Chiralpak ID-3 CSP; (ii) to
determine which of the two eluting enantiomers has (S)-conﬁg-
uration; (iii) to evaluate the retention times of (S)-OME and all its
chiral and achiral impurities under reversed-phase mode [mobile
phase: acetonitrile–water (50:50, v/v)].
Finally, the paper demonstrated that the enantioselective
method reported in the current Pharmacopoeias is not speciﬁc due
to the overlapping of IMP-A and the (R)-OME form. The proposed
enantioselective method is simple, rapid, sensitive and precise,
and can be adopted for routine use to establish the enantiomeric
purity of (S)-OME in raw materials or in working standards.Acknowledgments
On the occasion of his retirement, the authors wish to thank Dr.
Bruno Gallinella for his dedication to the lab and for being a dear
friend.References
[1] P.B. Kale-Pradham, H.K. Landry, W.T. Sypula, Esomeprazole for acid peptic
disorders, Ann. Pharmacother. 36 (2002) 655–663.
[2] T. Andersson, Single-isomer drugs: true therapeutic advances, Clin. Pharma-
cokinet. 43 (2004) 279–285.
[3] European Pharmacopoeia, supplement 8.2, Strasburg: European Directorate
for the Quality of Medicines and Health Care (EDQM), Council of Europe, 2014,
4028–4030.
[4] L. Olbe, E. Carlsson, P. Lindberg, A proton-pump inhibitor expedition: the case
histories of omeprazole and esomeprazole, Nat. Rev. Drug. Discov. 2 (2003)
132–139.
[5] K. Balmér, B.A. Persson, P.O. Lagerström, Stereoselective effects in the se-
paration of enantiomers of omeprazole and other substituted benzimidazoles
on different chiral stationary phases, J. Chromatogr. A 660 (1994) 269–273.
[6] S. Allenmark, B. Bomgren, H. Borén, et al., Direct optical resolution of a series
of pharmacologically active racemic sulfoxides by high-performance liquid
afﬁnity chromatography, Anal. Biochem. 136 (1984) 293–297.
[7] P. Erlandsson, R. Isaksson, P. Lorentzon, et al., Resolution of the enantiomers of
omeprazole and some of its analogues by liquid chromatography on a tri-
sphenylcarbamoylcellulose-based stationary phase: The effect of the en-
antiomers of omeprazole on gastric glands, J. Chromatogr. 532 (1990)
305–319.
[8] S. Dixit, R. Dubey, R. Bhushan, Normal and polar-organic-phase high-perfor-
mance liquid chromatographic enantioresolution of omeprazole, rabeprazole,
lansoprazole and pantoprazole using monochloro-methylated cellulose-based
chiral stationary phase and determination of dexrabeprazole, Biomed. Chro-
matogr. 28 (2014) 112–119.
[9] L.N. Chennuru, T. Choppari, S. Duvvuri, et al., Enantiomeric separation of
proton pump inhibitors on new generation chiral columns using LC and
B. Gallinella et al. / Journal of Pharmaceutical Analysis 6 (2016) 132–136136supercritical ﬂuid chromatography, J. Sep. Sci. 36 (2013) 3004–3010.
[10] S. Vyas, A. Patel, K.D. Ladva, et al., Development and validation of a stability
indicating method for the enantioselective estimation of omeprazole en-
antiomers in the enteric-coated formulations by high-performance liquid
chromatography, J. Pharm. Bioallied Sci. 3 (2011) 310–314.
[11] P. Estevez, S. Flor, O. Boscolo, et al., Development and validation of a capillary
electrophoresis method for determination of enantiomeric purity and related
substances of esomeprazole in raw material and pellets, Electrophoresis 35(2014) 804–810.
[12] L. Zanitti, R. Ferretti, B. Gallinella, et al., Direct HPLC enantioseparation of
omeprazole and its chiral impurities: Application to the determination of
enantiomeric purity of esomeprazole magnesium trihydrate, J. Pharm.
Biomed. Anal. 52 (2010) 665–671.
[13] R. Cirilli, R. Ferretti, B. Gallinella, et al., Retention behavior of proton pump
inhibitors using immobilized polysaccharide-derived chiral stationary phases
with organic-aqueous mobile phases, J. Chromatogr. A 1304 (2013) 147–153.
